Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2024-02-22 00:00:00 ET · period of report 2024-02-20 · accession 0000950170-24-018783 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-22 | 2024-02-20 | KLRS | Sinha Vikas | See Remarks, Dir, 10% | S - Sale | $0.7 | -2,893 | 1.14M | -0.3% | -$2,025 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-20 | S | D | 2,893 | $0.7 | 1,142,359 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6832 to $0.7150. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |